Enliven Therapeutics, Inc.
ELVN Healthcare
₹ 39.13
10.13%
Live Market Data
Market Cap₹ 234 Cr.
Current Price₹ 39.13
High / Low₹40.58 / 13.3
Stock P/E0.0
Book Value₹7.7
Dividend Yield0.00 %
ROCE-0.2 %
ROE-0.3 %
About Company
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Industry Segment
Biotechnology
Price Chart
Loading Chart...
Technical Analysis
Technical Outlook
Short TermBullish
Mid TermBullish
Long TermNeutral
Resistance₹39.130001068115234
Support₹21.345
Valuation Check
Fair Value Assessment
Overvalued
Research Reports
Daily – Vickers Top Buyers & Sellers for 01/14/2026
Daily – Vickers Top Buyers & Sellers for 11/14/2025
Quarterly Results
| Particulars | Dec 25 | Sept 25 | Jun 25 | Mar 25 | Dec 24 |
|---|---|---|---|---|---|
| Total Revenue (Cr) | 0 | 0 | 0 | 0 | 0 |
| Net Income (Cr) | -2.97 | -2.01 | -2.53 | -2.85 | -2.32 |
| EPS (₹) | -0.48 | -0.32 | -0.49 | -0.57 | -0.46 |
Annual Profit & Loss
| Particulars | 2025 | 2024 | 2023 | 2022 | 1970 |
|---|---|---|---|---|---|
| Total Revenue (Cr) | 0 | 0 | 0 | 0 | 0 |
| Operating Exp (Cr) | 11.97 | 10.46 | 8.35 | 3.88 | 0 |
| Net Income (Cr) | -10.37 | -8.9 | -7.16 | -3.77 | 0 |
| EPS (₹) | 0 | -1.89 | -2.01 | -0.92 | -0.6 |
Balance Sheet
| Particulars | Dec 25 | Sept 25 | Jun 25 | Mar 25 | Dec 24 |
|---|---|---|---|---|---|
| Total Assets (Cr) | 47.62 | 49.09 | 50.39 | 30.26 | 32.58 |
| Total Liabilities (Cr) | 1.66 | 1.48 | 1.54 | 1.43 | 1.59 |
| Total Equity (Cr) | 45.96 | 47.61 | 48.85 | 28.83 | 30.98 |
Key Ratios Fundamentals
Valuation
P/E Ratio (TTM)
-Forward P/E
-15.41PEG Ratio
-Price / Book
5.06EV / EBITDA
-13.92Profitability
ROE
-26.95%ROA
-18.65%Profit Margin
-Operating Margin
-Liquidity & Debt
Current Ratio
28.66Quick Ratio
27.92Debt / Equity
0.09Total Cash (Cr)
46.26Price Statistics
Beta
1.0652W High
40.5852W Low
13.30Dividend Yield
-Pattern Unavailable
Detailed shareholding breakdown is not currently provided by the exchange.